Contact
Please use this form to send email to PR contact of this press release:
FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19
TO:
Please use this form to send email to PR contact of this press release:
FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19
TO: